Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Vifor Pharma AG banner
V

Vifor Pharma AG
F:G2AB

Watchlist Manager
Vifor Pharma AG
F:G2AB
Watchlist
Price: 30.6 EUR Market Closed
Market Cap: €9.9B
Write Note Create Alert Ask AI

Wall St Price Targets

G2AB Price Targets Summary
Vifor Pharma AG

There are no price targets for G2AB.
G2AB Lowest Forecast
Wall Street Target
Not Available
G2AB Average Forecast
Wall Street Target
Not Available
G2AB Highest Forecast
Wall Street Target
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Vifor Pharma AG Competitors:
Price Targets

Revenue
Forecast

-8% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
-8% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 8 years, the compound annual growth rate for Revenue has been -8%. The projected CAGR for the next 3 years is 11%.

What are analyst estimates?

Gross Profit
Forecast

8% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
8% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Vifor Pharma AG

Operating Income
Forecast

-1% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
-1% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 8 years, the compound annual growth rate for Operating Income has been -1%. The projected CAGR for the next 3 years is 16%.

What are analyst estimates?

Pre-Tax Income
Forecast

-2% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-2% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Vifor Pharma AG

Net Income
Forecast

-9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Vifor Pharma AG

Continue G2AB Research

Summary
G2AB intrinsic value, competitors valuation, and company profile.
DCF Valuation
G2AB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
G2AB stock valuation using valuation multiples.
Wall St Estimates
G2AB price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
G2AB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Vifor Pharma AG listings:
LSE • CHF
0RPD
 F • EUR
G2AA
 SIX • CHF
VIFN
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is G2AB's stock price target?
Not Available

G2AB does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Vifor Pharma AG?
Projected CAGR
11%

Over the last 8 years, the compound annual growth rate for Revenue has been -8%. The projected CAGR for the next 3 years is 11%.

What is the Operating Income forecast for Vifor Pharma AG?
Projected CAGR
16%

Over the last 8 years, the compound annual growth rate for Operating Income has been -1%. The projected CAGR for the next 3 years is 16%.

Back to Top
ALPHA SPREAD
Follow us
Join 352,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett